Impact of restricted access to, and low awareness of, mexiletine on people with myotonia: a real-world European survey

Although mexiletine effectively treats myotonia, supply disruptions affected Europe between 2008- 2018. MyoPath was a mixed-methods, cross-sectional, market research survey conducted January- June 2018 to evaluate consequences of limited access to/awareness of mexiletine in people with myotonia. Part A: qualitative structured interviews (clinicians; advocates for adult patients); Part B: quantitative online questionnaire completed by people with self-reported history of myotonia. Part A: Interviews (clinicians, n = 12; patient advocates, n = 5; 12 countries) indicated poor mexiletine awareness among general neurologists. Patients chose between living with myotonia (other treatments were generally unsatisfactory) or importing mexiletine. Part B: Questionnaire respondents, myotonic dystrophy (DM)1, n = 213; DM2, n = 128; non-dystrophic myotonia (NDM), n = 41; other n = 8; (11 countries). Of the respondents, 76/390 (20%) people with awareness of/access to mexiletine described profound improvements in myotonia and health-related quality of life following treatment. Respondents with NDM had greatest mexiletine experience (n = 28/41). Mexiletine was associated with fewer falls, less muscle stiffness, increased mobility. Treatment interruptions worsened myotonia and were associated with fatigue, pain, dysphagia, breathing difficulty, impaired digestion, poor sleep. However, 36/54 (67%) of currently treated people expressed anxiety about mexiletine's availability: this finding was expected (MyoPath was undertaken before mexiletine's approval in NDM). MyoPath provides the largest European exploration of patients' views regarding impact of mexiletine on myotonia. Anticipated effects of mexiletine differ between people with different myotonic disorders: myotonia is the main symptom in NDM but one of many potential symptoms affecting those with DM. Nevertheless, findings indicate substantial harm caused to people with myotonia when mexiletine awareness/access is limited. (c) 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

Automated summary

Although mexiletine is effective in treating myotonia, supply disruptions in Europe from 2008 to 2018 have caused limited access and awareness of the drug. A mixed-methods, cross-sectional study was conducted to evaluate the consequences and awareness of mexiletine in people with myotonia, revealing poor awareness among general neurologists and significant improvements in myotonia and quality of life for those with access to the drug.